Trial · NCT02688140
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Event-free survival | From date of randomization until the date of first documented event, assessed up to 66 months | events are: no achievement of haematological complete remission after induction therapy; no achievement of molecular remission after the last consolidation course; relapse; death including early death or development of secondary AML or MDS |
| Secondary | Rate of hematological complete remission | up to 60 days, from date of randomization until end of induction therapy | |
| Secondary | Rate of early death within 30 days after randomization | up to 30 days after randomization | |
| Secondary | Rate of overall survival (OS) | at 2 years | |
| Secondary | Rate of cumulative incidence of secondary MDS or AML | assessed up to 66 months, from date of randomization until occurance of secondary AML or MDS | |
| Secondary | Rate of cumulative incidence of relapse (CIR) | at 2 years | |
| Secondary | Incidence of hematological and non-hematological toxicity | assessed up to 30 months after randomization | |
| Secondary | Rate of molecular remission after the last consolidation cycle | up to 256 days after randomization | |
| Secondary | Assessment of acute promyelocytic leukemia/RARa transcript level reduction after induction therapy until end of study | assessed up to 30 months after randomization | |
| Secondary | Quality of Life at the end of induction therapy until the end of study | assessed up to 30 months after randomization | |
| Secondary | To investigate differences in the immune reconstitution between the two arms | assessed up to 30 months after randomization | |
| Secondary | Total hospitalization days during therapy | assessed up to 30 months after randomization |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02688140/registered